About Metrion Biosciences
Metrion Biosciences is a company based in Cambridge (United Kingdom) founded in 2015.. Metrion Biosciences has raised $8.44 million across 5 funding rounds from investors including Gov.uk, Maven Capital Partners and Gresham House Ventures. Metrion Biosciences operates in a competitive market with competitors including Anabios, Clyde Biosciences, Quiver Bioscience, Zen-Bio and Rules-Based Medicine, among others.
- Headquarter Cambridge, United Kingdom
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Metrion Biosciences Ltd
- Date of Incorporation 03 Jul, 2015
- Jurisdiction CAMBRIDGE, UNITED KINGDOM
-
Annual Revenue
$6.54 M (USD)56as on Dec 31, 2022
-
Net Profit
$1.45 K (USD)101as on Dec 31, 2022
-
EBITDA
$-32.82 K (USD)84as on Dec 31, 2022
-
Total Equity Funding
$8.44 M (USD)
in 5 rounds
-
Latest Funding Round
$4.7 M (USD), Series B
Dec 20, 2023
-
Investors
Gov.uk
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Metrion Biosciences
Metrion Biosciences has successfully raised a total of $8.44M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $4.7 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series B — $4.7M
-
First Round
First Round
(05 Feb 2018)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2023 | Amount | Series B - Metrion Biosciences | Valuation | Maven Capital Partners | |
| Apr, 2021 | Amount | Seed - Metrion Biosciences | Valuation | Gresham House Ventures |
|
| Mar, 2019 | Amount | Seed - Metrion Biosciences | Valuation | o2h ventures |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Metrion Biosciences
Metrion Biosciences has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Gov.uk, Maven Capital Partners and Gresham House Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are targeted for private equity investments.
|
Founded Year | Domain | Location | |
|
Growth equity investments are made to scale high-potential businesses.
|
Founded Year | Domain | Location | |
|
Invests in biotech therapeutics and AI technologies through EIS funds.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Metrion Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Metrion Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Metrion Biosciences Comparisons
Competitors of Metrion Biosciences
Metrion Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Anabios, Clyde Biosciences, Quiver Bioscience, Zen-Bio and Rules-Based Medicine, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Ex-vivo human tissue studies are performed for preclinical drug discovery.
|
|
| domain | founded_year | HQ Location |
Cardiac safety testing is conducted using iPS-derived heart cells.
|
|
| domain | founded_year | HQ Location |
Developer of transformational medicines for neurological disorders
|
|
| domain | founded_year | HQ Location |
Cell-based solutions are provided to accelerate therapy discovery and development.
|
|
| domain | founded_year | HQ Location |
Multiplexed immunoassays for protein biomarkers are developed via proprietary platform.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Metrion Biosciences
Frequently Asked Questions about Metrion Biosciences
When was Metrion Biosciences founded?
Metrion Biosciences was founded in 2015 and raised its 1st funding round 3 years after it was founded.
Where is Metrion Biosciences located?
Metrion Biosciences is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Is Metrion Biosciences a funded company?
Metrion Biosciences is a funded company, having raised a total of $8.44M across 5 funding rounds to date.
What is the annual revenue of Metrion Biosciences?
Annual revenue of Metrion Biosciences is $6.54M as on Dec 31, 2022.
What does Metrion Biosciences do?
Metrion is a CRO specializing in ion channel screening, cardiac safety profiling and drug discovery services on a fee-for-service or collaboration basis. They offer services such as ion channel screening, cardiac safety panel screening (CiPA and hERG), neuroscience panels (neuroscience-related ion channel screening assays and platforms) and translational assays (phenotypic assays to aid the translation of in vitro cardiac safety and neuroscience data to the preclinical stage). They claim to have over 80 years of combined global ion channel research and drug discovery expertise and also in a wide range of ion channel gene families (Nav, Cav, Kv, hERG, TRP, GluR, nAChR), pain pharmacology, and synaptic transmission and plasticity. The company was formed by a management buyout from Xention Ltd., in October 2015.
Who are the top competitors of Metrion Biosciences?
Metrion Biosciences's top competitors include Quiver Bioscience, Anabios and Zen-Bio.
Who are Metrion Biosciences's investors?
Metrion Biosciences has 4 investors. Key investors include Gov.uk, Maven Capital Partners, Gresham House Ventures, and o2h ventures.